Targets › FTSJ1
2 programs from 1 company in 2 trials: 2 Phase 2; Infectious disease.
Methylates the 2'-O-ribose of nucleotides at positions 32 and 34 of the tRNA anticodon loop of substrate tRNAs. Requisite for faithful cytoplasmic translation. (UniProt, Q9UET6)
Open in Phaseline: the race on FTSJ1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University Hospital, Basel, Switzerland | Cefazolin Bacterial penicillin-binding protein inhibitor | FTSJ1 | Phase 2 | Complicated Staphylococcus Aureus (S. Aureus) Infections (CSAI) | – |
| University Hospital, Basel, Switzerland | Flucloxacillin (FLU) continuous infusion with TDM Beta-lactam antibiotic; inhibits bacterial cell wall synthesis by binding to penicillin-bi | FTSJ1 | Phase 2 | Complicated Staphylococcus Aureus (S. Aureus) Infections (CSAI) | – |
Complicated Staphylococcus Aureus (S. Aureus) Infections (CSAI) (2)
small molecule (2)
University Hospital, Basel, Switzerland (2)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.